Proton Pump Inhibitor Formulary Considerations in the Acutely III: Part 1: Pharmacology,Pharmacodynamics,and Available Formulations

Abstract

Spanish

Objective:

To review important proton pump inhibitor (PPI) pharmacologic, pharmacokinetic, and pharmacodynamic principles in acutely ill patients, compare PPI formulation options for patients unable to swallow a tablet or capsule, and provide clinicians with guidance when making hospital formulary decisions with this class of agents.

Data Sources:

MEDLINE (1966–May 2005) and the Cochrane Library databases were searched using the key words proton pump inhibitor, acid suppression, peptic ulcer disease, gastrointestinal bleeding, stress ulcer prophylaxis, and critical illness. Bibliographies of cited references were reviewed, and a manual search of abstracts from recent gastroenterology, critical care, and surgery scientific meetings was completed.

Study Selection and Data Extraction:

All articles identified from the data sources were evaluated, and all information deemed relevant was included for this review.

Data Synthesis:

PPIs have become a mainstay for acute acid suppression in hospitalized patients over other therapeutic options. Various commercially available PPI products are available for administration, either enterally or parenterally, to patients unable to swallow a tablet or capsule. Newer oral PPI formulations offer numerous advantages over older products. The results of studies comparing the pharmacokinetics and pharmacodynamics of different PPI dosage forms and routes of administration are among the factors to consider when making formulary decisions.

CONCLUSIONS:

While the introduction of new PPI products has expanded the therapeutic options for acid suppression in acutely ill patients, a number of unresolved questions remain surrounding the interchangeability of these products, the clinical significance of one PPI formulation over the other, and how oral/enteral PPI therapy should be used as step-down therapy after parenteral PPI therapy.

Keywords

critical care decision-making proton pump inhibitors.

Get full access to this article

View all access options for this article.

References

Berardi

Welage

. Evaluation of omeprazole, lansoprazole, pantoprazole and rabeprazole in the treatment of acid-related disorders. J Am Pharm Assoc 2000; 40: 52–62.

Metz

Pratha

Martin

Paul

Maton

Lew

, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 626–33.

Pisegna

. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med 2002; 30 (suppl): S356–61.

Conrad

. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med 2002; 30 (suppl): S365–8.

Welage

Ellis

Alaniz

. Gastrointestinal alterations in the critically ill. Pharm Pract News 2003; 7 (August): 46–51.

Balaban

Duckworth

Peura

. Nasogastric omeprazole: effects on gastric pH in critically ill patients. Am J Gastroenterol 1997; 92: 79–83.

Phillips

Metzler

Palmieri

Huckfeldt

Dahl

. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24: 1793–800.

Sharma

. Comparison of 24–hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56 (suppl 4): S18–21.

Baldi

Malfertheiner

. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1–5.

10.

Sostek

Chen

Skammer

Winter

Zhao

Andersson

. Esomeprazole administered through nasogastric tube provides bioavailability similar to oral dosing. Aliment Pharmacol Ther 2003; 18: 581–6.

11.

Package insert. Zegerid (omeprazole). San Diego: Santarus. www.santarus.com/pdf/package_insert.pdf (accessed 2005 May 12).

12.

Package insert. Prevacid Solutab (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products. www.pitap.abbott.com/prevacidsolutab.pdf (accessed 2005 May 12).

13.

Package insert. Prevacid IV (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products. www.pitap.abbott.com/prevacidiv.pdf (accessed 2005 May 12).

14.

Package insert. Protonix IV (pantoprazole). Madison, WI: Wyeth Pharmaceuticals. www.wyeth.com/content/ShowLabeling.asp?id=469 (accessed 2005 May 12).

15.

Package insert. Nexium (esomeprazole). Wilmington, DE: Astra-Zeneca PLC. www.astrazeneca-us.com/pi/Nexium.pdf (accessed 2005 May 12).

16.

Package insert. Nexium IV (esomeprazole). Wilmington, DE: Astra-Zeneca PLC. www.astrazeneca-us.com/pi/Nexium.pdf (accessed 2005 May 12).

17.

Hellstrom

Vitols

. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004; 94: 106–11.

18.

Pisegna

. Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 2001; 32: 27–32.

19.

Zuckerman

. A prescription for sanity. US News World Rep 2004 (Nov 22);137(18): 80.

20.

Kaplan

Bates

McDonald

. Inappropriate use of intravenous proton pump inhibitors: problem extent and cost implications (abstract). Am J Gastroenterol 2002; 97: S236.

21.

Enns

Andrews

Fishman

Hahn

Atkinson

Kwan

, et al. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicenter study. Can J Gastroenterol 2004; 18: 561–71.

22.

Cornish

Papastergiou

Saibil

. Audit of IV pantoprazole: patterns of use and compliance with guidelines. Can J Hosp Pharm 2002; 55: 20–6.

23.

Modlin

Sachs

. Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag, 2004: 180–202.

24.

Metz

Ferron

Paul

Turner

Soffer

Pisegna

, et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J Clin Pharmacol 2002; 42: 512–9.

25.

Welage

. Pharmacologic properties of the proton pump inhibitors: comparing the agents. Pharmacotherapy 2003; 23 (suppl): 74S–80S.

26.

Richardson

Hawkey

Stack

. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307–35.

27.

Merki

Wilder-Smith

. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60–4.

28.

Kromer

. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995; 56: 443–54.

29.

Besancon

Simon

Sachs

Shin

. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438–46.

30.

Wolfe

Sachs

. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118 (suppl): S9–31.

31.

Lasky

Metzler

Phillips

. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998; 44: 527–33.

32.

Conrad

Gabrielli

Margolis

Quartin

Hata

Frank

, et al. Randomized, double-blind comparison of immediate-release omeprazole-oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33: 760–5.

33.

Barkun

Bardou

Marshall

. Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 843–57.

34.

Dubois

. Control of gastric acid secretion. In: Brandt

Daum

Friedman

, eds. Clinical practice of gastroenterology. Philadelphia: Clinical Medicine, Inc., 1999: 180–8.

35.

Andersson

Hassan-Alin

Hasselgren

Rohss

Weidolf

. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411–26.

36.

Package insert. Prevacid (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products. www.pitap.abbott.com/prevacid.pdf (accessed 2005 May 12).

37.

Package insert. Aciphex (rabeprazole). Titusville, NJ: Janssen Pharmaceutica. www.janssen.com/active/janus/en_US/assets/jan/aciphex.pdf (accessed 2005 May 12).

38.

Package insert. Protonix (pantoprazole) delayed release tablet. Madison, WI: Wyeth Pharmaceuticals. www.wyeth.com/content/ShowLabeling.asp?id=135 (accessed 2005 May 12).

39.

Yasuda

Ohnishi

Ogawa

Tomono

Hasegawa

Nakai

, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994; 32: 466–73.

40.

Hassan-Alin

Andersson

Bredberg

Rohss

. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665–70.

41.

Andersson

Andren

Cederberg

Lngerstrom

Lundborg

Skanberg

. Pharmacokinetics of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557–63.

42.

Ching

Mihaly

Angus

Morgan

Devenish-Meares

Yeomans

, et al. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991; 31: 166–70.

43.

Delhotal-Landes

Cournot

Vermerie

Dellatolas

Benoit

Foouvat

. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991; 3: 315–20.

44.

Spencer

Faulds

. Esomeprazole. Drugs 2000; 60: 321–9.

45.

Pilbrant

Cederberg

. Development of an oral formulation of omeprazole. Scand J Gastroenterol 1985; 10 (suppl): 113–20.

46.

Thomson

Sinclair

Matisko

Rosen

Andersson

Olofsson

. Influence of food on the bioavailability of an enteric coated tablet formulation of omeprazole 20 mg under repeated dose conditions. Can J Gastroenterol 1997; 11: 663–7.

47.

Freston

Kukulka

Lloyd

Lee

. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment Pharmacol Ther 2004; 20: 407–11.

48.

Freston

Chiu

Mulford

Ballard

. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrated tablets in healthy volunteers. Aliment Pharmacol Ther 2003; 17: 361–7.

49.

Stedman

Barclay

. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963–78.

50.

Sakai

Aoyama

Kita

Sakaeda

Nishiguchi

Nishitora

, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18: 721–7.

51.

Furuta

Ohashi

Kamata

Takashima

Kosuge

Kawasaki

, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027–30.

52.

Furuta

Ohashi

Kosuge

Zhao

Takashima

Kimura

, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552–61.

53.

Leontiadis

Sharma

Howden

. Systemic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia—a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005; 21: 1055–61.

54.

Package insert. Prilosec (omeprazole). Wilmington, DE: Astra-Zeneca PLC. www.astrazeneca-us.com/pi/Prilosec.pdf (accessed 2005 May 12).

55.

Phillips

Olsen

Rebuck

Rangnekar

Miedema

Metzler

. A randomized, pharmacokinetic and pharmacodynamic, crossover study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 2001; 96: 367–72.

56.

Mann

Fuhs

Cerra

. Pharmacokinetics and pharmacodynamics in critically ill patients. World J Surg 1987; 11: 210–7.

57.

Hastings

Skillman

Bushnell

Silen

. Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients. N Engl J Med 1978; 298: 1041–5.

58.

Green

Kaplan

Curtis

Levine

. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38–43.

59.

Brunner

Luna

Hartmann

Wurst

. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Bio Med 1996; 69: 225–31.

60.

Brunner

Thiesemann

. The potential clinical role of intravenous omeprazole. Digestion 1992; 51 (suppl): 17–20.

61.

Barkun

Racz

van Rensburg

Beglinger

Kupcinskas

Schaefer-Preuss

, et al. Prevention of peptic ulcer rebleeding using continuous infusion of pantoprazole vs ranitidine: a multicenter, multinational, randomized, double-blind, parallel-group comparison (abstract). Gastroenterology 2004; 126: A78.

62.

Metz

Amer

Hunt

. Establishing a regimen for lansoprazole administration to markedly inhibit acid output in normal volunteers (abstract). Presented at: Digested Diseases Weekly Meeting, Chicago, IL, May 18, 2005.

63.

Roberts

Pitcher

Cryer

. Effect of lansoprazole suspension versus continuous intravenous ranitidine on gastric pH of mechanically ventilated intensive care unit patients (abstract). Crit Care Med 2000; 28: 567.

64.

Somberg

Karlstadt

Blatcher

McDevitt

Graepel

Paoletti

, et al. Intermittent intravenous pantoprazole maintains control of gastric pH in intensive care unit patients (abstract). Am J Gastroenterol 2002; 97: S47.

65.

Tutuian

Castell

Xue

Katz

. The acidity index: a simple approach to the measurement of gastric acidity. Aliment Pharmacol Ther 2004; 19: 443–8.

66.

Armstrong

Bair

James

Tanser

Escobedo

Nevin

. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705–11.

67.

Taubel

Sharma

Chiu

Lukasik

Pilmer

Pan

. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-hour intragastric pH. Aliment Pharmacol Ther 2001; 11: 1807–17.

68.

Gremse

Donnelly

Kukulka

Lloyd

Lee

. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211–5.

69.

McAndrews

Jr Eastham

. Omeprazole and lansoprazole suspensions for nasogastric administration (letter). Am J Health Syst Pharm 1999; 56: 81.

70.

Dunn

White

Reddy

Quercia

Chow

MSS

. Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro. Am J Health Syst Pharm 1999; 56: 2327–30.

71.

DiGiacinto

Olsen

Bergman

Hoie

. Stability of suspension formulations of lansoprazole and omeprazole in amber-colored plastic syringes. Ann Pharmacother 2000; 34: 600–5. DOI 10.1345/aph.19086

72.

Kane

. Administration of omeprazole (Prilosec) in the atypical patient (letter). Int J Pharmaceut Comp 1997; 1: 13.

73.

Peckman

. Alternative method for administering proton-pump inhibitors through nasogastric tubes (letter). Am J Health Syst Pharm 1999; 56: 1020.

74.

Chun

Shi

Achari

Dennis

Cavanaugh

. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 1996; 18: 833–42.

75.

White

Kalus

Quercia

Fortier

Piotrowski

Roach

, et al. Delivery of esomeprazole magnesium enteric-coated pellets through small caliber and standard nasogastric tubes and gastronomy tubes in vitro. Am J Health Syst Pharm 2002; 59: 2085–8.

76.

Phillips

Metzler

. Simplified omeprazole solution for the prophylaxis of stress-related mucosal damage in critically ill patients (abstract). Crit Care Med 1994; 22: A53.

77.

Ferron

Sherry

Abell

Unruh

Getsy

Mayer

, et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health Syst Pharm 2003; 60: 1324–9.

78.

Olsen

Bergman

Kaufman

Rebuck

Collier

. Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. Pediatr Crit Care Med 2001; 2: 232–7.

79.

Kaufman

Lyden

Brown

Davis

Andersen

Olsen

, et al. Omeprazole therapy in pediatric liver and intestinal transplantation. J Pediatr Gastroenterol Nutr 2002; 34: 194–8.

80.

Phillips

Metzler

Huckfeldt

Olsen

. A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcers (abstract). Crit Care Med 1998; 26 (suppl): A101.

81.

Sharma

Peyton

Spears

Raufman

Howden

. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14: 887–92.

82.

Phillips

Metzler

Olsen

. The stability of simplified lansoprazole suspension (SLS) (abstract). Gastroenterology 1999; 116A: G0382.

83.

Dentinger

Swenson

Anaizi

. Stability of pantoprazole in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 2002; 59: 953–6.

84.

Tolia

Johnston

Stolle

Lee

. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup. Pediatr Drugs 2004; 6: 127–31.

85.

Walker

Fan-Lun

Wyllie

Iazzetta

Law

. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004; 57: 90–7.

86.

Partsch

Paladino

. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. Ann Pharmacother 1997; 31: 1137–45.